Eli Lilly to acquire cancer drug developer
15-05-2018
Japanese Takeda to acquire Shire for $62bn
08-05-2018
Roche to make $1.9bn acquisition
19-02-2018
designer491 / iStockphoto.com
Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, mergers & acquisitions, M&A, Armo Biosciences, immuno-oncology, immunotherapies, oncology
